Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin

Baghai, Fereshteh; Yazdani, Farzad; Etebarian, Arghavan; Garajei, Ata; Skálová, Alena

doi:10.1016/j.prp.2017.07.017

Cited by 58 publications

(46 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Locally recurrent disease was present as a component of relapse in the vast majority of cases in which nodal or distant relapse also occurred. In the six cases that experienced distant relapse in which the distribution of disease has been described, the lungs were the primary site of involvement in most cases . There was additional involvement of the pleura, pericardium, or mediastinum in three cases and in two cases was there extrathoracic disease with spread to liver or bone .…”

Section: Discussionmentioning

confidence: 93%

“…In addition, we reviewed all published cases of SC in which follow‐up data of 6 months or greater were available by conducting a PubMed search using the terms “mammary analog secretory carcinoma,” “mammary analogue secretory carcinoma,” “secretory carcinoma,” and “MASC.” SC‐like tumors of nonsalivary gland origin were excluded. We identified 26 case reports and series totaling 170 patients with reported outcome data as shown in Table . Patient data from all publications were combined in order to assess recurrence rate and pattern.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Secretory carcinoma of the major salivary gland: Provincial population‐based analysis of clinical behavior and outcomes

Ayre

Hyrcza

et al. 2018

Head & Neck

View full text Add to dashboard Cite

Background Our aim was to identify the number of cases of secretory carcinoma (SC) of the major salivary gland in a population‐based cohort and review its clinical behavior with long‐term follow‐up. Methods All malignant salivary gland tumors (MSGTs) diagnosed between 1980 and 2014 were assessed for histological features compatible with SC and 140 were selected for further analysis. Results Twenty two new cases of SC were identified, 19 of which were originally classified as acinic cell carcinoma, and 3 as adenocarcinoma, not otherwise specified (NOS). Lymph node involvement was less common in SC tumors (5%) than in the control group (11%). Disease recurrence was seen less frequently in SC (9%) than the control group (20%). Mean disease‐free survival was 192 months for SC compared with 162 months for controls (P = 0.15). Conclusion The clinical course of SC is typically indolent with a low risk of relapse not significantly different from other low‐grade MSGT.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Methodsmentioning

confidence: 99%

Secretory carcinoma of the major salivary gland: Provincial population‐based analysis of clinical behavior and outcomes

Ayre

Hyrcza

et al. 2018

Head & Neck

View full text Add to dashboard Cite

show abstract

“…Infantile fibrosarcoma, which is a rare myofibroblastic/fibroblastic tumor and carries ETV6‐NTRK3 translocation, had a rapid response to selective tropomyosin‐related kinase inhibitor LOXO‐101 . The correct diagnosis of SC is necessary for appropriate therapy, particularly when a high‐grade transformation occurs . In addition, SC shows a slightly higher lymph node metastatic rate, and MRI findings and immunohistochemical panels of SC are useful for managing the patient.…”

Section: Discussionmentioning

confidence: 99%

“…Genuine high‐grade transformation has been reported in some SC cases . With the expansion of selective tyrosine kinase inhibitors, recognition of advanced‐stage SC eventually has direct therapeutic relevance . Therefore, distinguishing SC from ACC is important.…”

Section: Introductionmentioning

confidence: 99%

Hemorrhage of MRI and Immunohistochemical Panels Distinguish Secretory Carcinoma From Acinic Cell Carcinoma

Kuwabara

Yamamoto

Takato

et al. 2018

Laryngoscope Investig Oto

View full text Add to dashboard Cite

ObjectivesSecretory carcinoma (SC, mammary analogue secretory carcinoma) is a salivary gland tumor with ETV6‐NTRK3 gene fusion, and its differential diagnosis includes acinic cell carcinoma (ACC). As hemorrhage is often seen in SC, we hypothesized that magnetic resonance imaging (MRI) and immunohistochemical analyses could distinguish SC from ACC.Study DesignRetrospective study.MethodsWe used ETV6‐NTRK3 gene fusion analyses to reclassify 19 parotid gland tumors that had previously been diagnosed as SC or ACC, and then investigated hemorrhage in both hematoxylin‐eosin (H&E)‐stained sections and MRIs, and immunohistochemical expression of S‐100, mammaglobin, DOG1, and α‐amylase.ResultsThe 19 tumors were genetically reclassified into 11 (58%) SC and 8 (42%) ACC. Combined S‐100 and mammaglobin were specific for SC; whereas DOG1 was specific for ACC, and α‐amylase was expressed only in 4 ACC cases (50%). H&E staining showed hemorrhage with hemosiderin deposition in all SC cases, and T2‐weighted MRI showed hypointense areas in all investigated SC cases, but not in ACC.ConclusionHemorrhage with hemosiderin deposition is frequently present in SC, and hemorrhage findings in MRI and an immunohistochemical panels for S‐100, mammaglobin and DOG1 can distinguish SC from ACC.Level of Evidence3b

show abstract

“…Acinic cell carcinoma typically is positive for DOG1, which demonstrates a canalicular staining pattern, and the majority of cases are negative for mammaglobin and S100 . In contrast, its most frequent mimic, secretory carcinoma, often demonstrates mammaglobin and S100 staining, and usually is DOG1 negative (or may demonstrate nonspecific cytoplasmic staining) . Some authors also have reported that carbonic anhydrase VI positivity can distinguish acinic cell carcinoma from secretory carcinoma .…”

Section: Introductionmentioning

confidence: 99%

Ancillary testing in salivary gland cytology: A practical guide

Krane

2018

Cancer Cytopathology

View full text Add to dashboard Cite

Salivary gland cytology is challenging, and historically the role of ancillary testing has been limited. However, numerous molecular/genetic advances in the understanding of salivary gland neoplasms during the last decade have facilitated the development of many useful diagnostic markers, such as PLAG1 and HMGA2 immunohistochemistry for pleomorphic adenoma and ETV6 fluorescence in situ hybridization for secretory carcinoma. Numerous salivary gland neoplasms are characterized by specific molecular/genetic alterations, many of which can be identified on cytologic preparations by karyotype analysis, fluorescence in situ hybridization, or immunohistochemical surrogates. Next-generation sequencing also has potential diagnostic applications, although to the authors' knowledge it currently has no routine role in salivary cytology. The primary goal of salivary fine-needle aspiration (FNA) is to facilitate appropriate clinical management. Ancillary testing has greatly enhanced the ability for accurate classification as per The Milan System for Reporting Salivary Gland Cytopathology and allows for the definitive diagnosis of many salivary FNA specimens, and also may resolve diagnostic uncertainty for FNAs that may be classified in The Milan System for Reporting Salivary Gland Cytopathology categories of salivary gland neoplasm of uncertain malignant potential or suspicious for malignancy. This review provides an updated discussion of the molecular/genetic features of the more commonly encountered salivary neoplasms by FNA, and discusses the application of available diagnostic immunohistochemical and molecular tests in salivary gland cytology.

show abstract

Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin

Cited by 58 publications

References 36 publications

Secretory carcinoma of the major salivary gland: Provincial population‐based analysis of clinical behavior and outcomes

Secretory carcinoma of the major salivary gland: Provincial population‐based analysis of clinical behavior and outcomes

Hemorrhage of MRI and Immunohistochemical Panels Distinguish Secretory Carcinoma From Acinic Cell Carcinoma

Ancillary testing in salivary gland cytology: A practical guide

Contact Info

Product

Resources

About